Key result
Hypokalemia-induced arrhythmias in heart failure are initiated by reduced Na+/K+-ATPase activity leading to calcium overload, suggesting CaMKII inhibition and NKA activation as potential therapies.
This review highlights that hypokalemia-induced arrhythmias in heart failure are driven by NKA inhibition and subsequent calcium overload, suggesting potential new antiarrhythmic targets.
Hypothesis-generating for CaMKII/NKA-targeted antiarrhythmics in hypokalemic HF; prospective trials needed before any clinical consideration.
Routine use of diuretics and neurohumoral activation make hypokalemia (serum K+< 3.5 mM) a prevalent electrolyte disorder among heart failure patients, contributing to the increased risk of ventricular arrhythmias and sudden cardiac death in heart failure. Recent experimental studies suggest that hypokalemia-induced arrhythmias are initiated by reduced activity in the Na+/K+-ATPase (NKA), subsequently leading to Ca2+ overload, Ca2+/Calmodulin dependent kinase II (CaMKII) activation and development of afterdepolarizations. In this article, we review the current evidence of mechanisms for hypokalemia-induced triggered arrhythmias, and how molecular changes in heart failure might lower the threshold for these arrhythmias. Finally, we discuss how the recent new insights in hypokalemia-
No takes yet. Share an insight, caveat, or question.
Skogestad et al. (2018) conducted a review in Heart failure and hypokalemia-induced arrhythmias. Hypokalemia-induced arrhythmias in heart failure are initiated by reduced Na+/K+-ATPase activity leading to calcium overload, suggesting CaMKII inhibition and NKA activation as potential therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: